ImmunID Appoints Veteran Industry Executive Bernhard Sixt as New CEO
7/24/2013 6:56:47 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
ImmunID Appoints Veteran Industry Executive Bernhard Sixt as new CEO
GRENOBLE, France--(BUSINESS WIRE)-- ImmunID, the pioneer in molecular immune diagnostics, today announced the appointment of Dr. Bernhard Sixt as president and chief executive officer. Dr. Sixt is co-founder and former CEO of Agendia, a leading molecular diagnostics company. Dr. Nicolas Pasqual, ImmunID’s co-founder and former chief executive officer, has been appointed chief scientific officer.
Nicolas Pascal, said, “Bernhard Sixt has deep experience in molecular diagnostics. As a co-founder and CEO he built Agendia from a fledgling start-up into an internationally recognized innovator in molecular cancer diagnostics. We are pleased to have attracted him and I warmly welcome Dr. Sixt to help us bring ImmunID to the next level of molecular diagnostics: precision medicine.”
Bernhard Sixt, CEO, said, “ImmunID has succeeded in establishing a reliable platform that yields high quality first-in-class molecular immune diagnostics, and a solid patent portfolio in one of the most exciting emerging fields in the diagnostics space. I look forward to using my experience in further building the company and leading the effort to further establish ImmunID’s leadership together with Nicolas Pasqual and his highly skilled team.”
Dr. Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare), and Nycomed (now part of Takeda). He is a co-founder of Agendia and has served as the company’s CEO from 2003 until 2011. Dr. Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University, and a PhD from the Technical University, both in Munich, Germany.
ImmunID is pioneering the field of molecular immune diagnostics since 2005, offering two commercial products. Its proprietary CE-marked flagship product ImmunTraCkeR evaluates the T cell receptor repertoire diversity at the genomic level. The company is ISO9001 certified and runs an ISO13485 accredited research and production facility in the MINATEC high-tech campus in Grenoble, France, and provides research and testing services worldwide to leading clinical centers and blue-chip pharmaceutical companies such as Roche and Sanofi-Pasteur. http://www.immunid.com
Hans Herklots, +41 79 598 7149
Bernhard Sixt, +33 438 785 770
President and CEO
Help employers find you! Check out all the jobs and post your resume.
comments powered by